SAN DIEGO — Artis BioSolutions has appointed Dr. Kate Broderick, Ph.D., as its new Chief Scientific Innovation Officer, effective February 9, 2026, as the company moves to strengthen its scientific leadership and advance its synthetic DNA strategy ahead of the planned acquisition of Syngoi Technologies.
In her new role, Dr. Broderick will lead scientific strategy, advocacy, and innovation initiatives across the Artis platform, supporting the company’s goal of building an integrated ecosystem for the development and manufacturing of next-generation genetic medicines.
Artis said the appointment comes as demand continues to grow for high-quality technologies that enable advanced therapies, prompting the company to expand its leadership team to accelerate innovation. Dr. Broderick brings more than 25 years of global life sciences experience, with deep expertise in nucleic acid medicine, DNA- and RNA-based vaccine development, and drug delivery technologies.
Most recently, she served as Chief Innovation Officer at Maravai LifeSciences, where she led the strategic expansion of the company’s innovation engine through a combination of internal development efforts and external licensing opportunities.
Before that, Dr. Broderick was Senior Vice President of Research and Development at Inovio Pharmaceuticals, where she led multidisciplinary teams working on DNA-based vaccines, therapeutics, and delivery platforms. During her tenure, she advanced multiple clinical-stage programs, including overseeing the development of a DNA-based COVID-19 vaccine through Phase 3 testing. She also served as Principal Investigator on the first Lassa fever vaccine trial conducted in West Africa.
In addition, Dr. Broderick played a key role in securing more than $100 million in non-dilutive funding from U.S. government agencies and global organizations, including CEPI, the World Health Organization, and the Gates Foundation.
“Kate’s scientific depth and proven leadership in nucleic acid technologies make her uniquely positioned to help drive our synthetic DNA strategy forward,” said Brian Neel, Co-Founder and CEO of Artis BioSolutions. “As we move toward closing the Syngoi transaction, her experience scaling innovation platforms and translating advanced DNA technologies into clinical programs will be critical to our integration and long-term growth.”
Dr. Broderick earned her Ph.D. in Molecular Genetics from the University of Glasgow and completed her postdoctoral training at the University of California, San Diego, focusing on drug development. She has authored more than 100 peer-reviewed scientific publications and is an inventor on multiple patents related to nucleic acid-based vaccine and therapeutic technologies.
“Joining Artis at this pivotal moment represents an opportunity to help shape the future of synthetic DNA and its role in unlocking next-generation therapies,” Dr. Broderick said. “I look forward to working across Artis, Syngoi, and Landmark Bio to accelerate innovation and strengthen the infrastructure supporting the new wave of life changing genetic medicines.”
Artis BioSolutions said the proposed acquisition of Syngoi Technologies is expected to close in the first quarter of 2026, subject to customary closing conditions. Landmark Bio, the company’s inaugural acquisition, established Artis’ foundation in integrated development and GMP manufacturing capabilities to support advanced therapies.
